ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, announced today that it has appointed Sarah Reiter as Vice President, Business Development. In this role, Ms. Reiter will drive new business opportunities at Calyxt to support the company’s recently announced go-to-market strategies.
Ms. Reiter is a plant-based technology and agribusiness leader focused on establishing world-class partnerships and value chains that lead to the successful commercialization of emerging technologies for start-up, early-stage and Fortune 500 companies. She will apply her expertise in international business development, acquisitions and product portfolio management in agribusiness to develop, refine and implement the overall commercial strategy for Calyxt's future products, including the prioritization of markets, customers and product types.
“Calyxt continues to build momentum with our go-to-market strategies, and the addition of Sarah to the leadership team will help us to optimize and execute on these strategies going forward,” said Jim Blome, CEO of Calyxt. “Her proven success in the plant-based innovation sector is an ideal match for our technology, positioning us to be even more responsive to evolving consumer, sustainability and marketplace demands,” concluded Blome.
With more than 25 years of expertise in agribusiness, Ms. Reiter most recently served as the chief commercial officer of Arcadia Biosciences where she led the company’s commercial and product portfolio strategies and sales to consumer-packaged goods companies globally. Prior to Arcadia Biosciences, Ms. Reiter served as the CEO of Stockton U.S.A. with oversight of the U.S. division of the global multinational bio-ag company from inception to initial sales. She earned her Master’s Certificate in Business Analysis from the Villanova School of Continuing Education and her Bachelor’s degree from the University of California, Davis.
Calyxt (NASDAQ: CLXT), based in Roseville, Minnesota, is a technology company with a mission to deliver plant-based innovations for a better world. Founded in 2010, Calyxt uses its proprietary TALEN® gene editing technology to work with world-class partners via technology licensing, product development, and seed sale arrangements to revolutionize the way the world uses plants to solve problems. For further information, please visit our website at www.calyxt.com.
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” “will,” or “continue,” the negative of these terms and other similar terminology. Forward-looking statements in this press release include statements about the long term goals and future performance of our business. These and other forward-looking statements are predictions and projections about future events and trends based on our current expectations, objectives and intentions and premised on current assumptions. Our actual results, level of activity, performance or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: the severity and duration of the evolving COVID-19 pandemic and the resulting impact on macro-economic conditions; the impact of increased competition; disruptions at our key facilities; changes in customer preferences and market acceptance of our products; competition for collaboration partners and the successful execution of collaborations; the impact of adverse events during development, including unsuccessful field trials or disruptions in seed production; failures by third-party contractors; inaccurate demand forecasting; disruptions to supply chains, including transportation and storage functions; commodity price conditions; the impact of changes or increases in oversight and regulation; disputes or challenges regarding intellectual property; proliferation and continuous evolution of new technologies; management changes; dislocations in the capital markets; and other important factors discussed under the caption entitled “Risk Factors” in our Annual Report on Form 10-K and subsequent filings on Form 10-Q or 8-K with the U.S. Securities and Exchange Commission. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.